# Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

> **NCT04670978** · PHASE2 · UNKNOWN · sponsor: **Shandong University** · enrollment: 96 (estimated)

## Conditions studied

- Objective Response Rate

## Interventions

- **DRUG:** albumin-bound paclitaxe combined with bevacizumab biosimilar

## Key facts

- **NCT ID:** NCT04670978
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-31
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670978, "Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04670978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*